http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Quanterix to Participate at the Scotiabank Healthcare 1x1 Day
-
Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
-
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
-
Quanterix Releases Financial Results for the First Quarter of 2024
-
Quanterix To Report First Quarter 2024 Financial Results
-
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
-
Quanterix (QTRX) Granted FDA Breakthrough Device Designation for p-Tau 217 Test
-
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
-
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
-
Quanterix (QTRX) Reaffirms 2023 Guidance
-
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
-
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease
-
Quanterix to Present at Cowen’s 44th Annual Health Care Conference
-
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
-
Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference
-
Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Quanterix Releases Operating Results for Third Quarter 202
-
Quanterix to Report Third Quarter 2023 Financial Results on November 7, 2023
-
Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease
-
Quanterix (QTRX) Enters New Agreement to Advance Blood Based Alzheimer's Disease Detection
-
Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection
-
Quanterix CEO to Speak at Goldman Sachs Alzheimer’s Disease Day
-
Quanterix to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
-
Quanterix (QTRX) Appoints William P. Donnelly to its Board
-
William P. Donnelly Appointed to Quanterix’s Board of Directors
-
Quanterix (QTRX) Appoints Vandana Sriram as CFO
-
Quanterix Appoints Vandana Sriram as Chief Financial Officer
-
Quanterix Releases Operating Results for Second Quarter 2023
-
Quanterix to Present at Canaccord Genuity 43rd Annual Growth Conference
-
Quanterix’s Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients
-
Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023
-
Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer’s Disease in Patients
-
Quanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference
-
Quanterix Releases Operating Results for First Quarter 2023
-
Quanterix’s First Quarter 2023 Earnings Conference Call
-
Quanterix (QTRX) Announces FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials
-
FDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic Trials
-
Quanterix to Participate in Barclays Global Healthcare Conference
-
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations
-
Quanterix to Present at Cowen’s 43rd Annual Health Care Conference
-
Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call
-
Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call
-
Quanterix (QTRX) Announces Appointment of Brian Blaser to Board of Directors
-
Quanterix Announces Appointment of Brian Blaser to Board of Directors
-
Quanterix Expands Laboratory Developed Test Menu with Launch of Neurofilament Light Chain Test
-
Quanterix to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
-
Quanterix to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force
-
Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
-
Quanterix Corporation Releases Operating Results for Third Quarter 2022

